Albert, MC;
Uranga-Murillo, I;
Arias, M;
De Miguel, D;
Peña, N;
Montinaro, A;
Varanda, AB;
... Walczak, H; + view all
(2024)
Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality.
Cell Death & Differentiation
10.1038/s41418-024-01278-6.
(In press).
Preview |
Text
s41418-024-01278-6.pdf - Published Version Download (6MB) | Preview |
Abstract
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Archive Staff Only
 |
View Item |
